Mortality in nonalcoholic fatty liver disease: Clues from the cremona study

Hepatology

Volumn 54, Issue 1, 2011, Pages 6-8

  Adams, Leon A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

BODY MASS; CANCER MORTALITY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART DEATH; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC DISORDER; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NOTE; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; WAIST CIRCUMFERENCE;

ALGORITHMS; BODY MASS INDEX; FATTY LIVER; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; ITALY; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 79959548471     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24445     Document Type: Note

References (20)

1. Osler W. The evolution of modern medicine: A series of lectures delivered at Yale University on the Silliman Foundation. Fairford, UK: Echo Library; 1913.
2. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-219.
3. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
4. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206.
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
6. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1093-1097.
7. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al. Fatty liver index (FLI) and mortality: The cremona study at the 15(th) year of follow up. HEPATOLOGY 2011; 54: 145-152.
8. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
9. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104.
10. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
11. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
12. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006; 44: 865-873.
13. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. HEPATOLOGY 2009; 50: 1403-1411.
14. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. HEPATOLOGY 2010; 51: 595-602.
15. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-1573.
16. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
17. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136: 477-485.
18. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16: 1278-1286.
19. Verrijken A, Francque S, Mertens I, Talloen M, Peiffer F, Van Gaal L. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes (Lond) 2010; 34: 899-907.
20. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler MG, Brenner DA, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010; 139: 836-845.